• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 863-873.DOI: 10.3969/j.issn.1671-2587.2026.05.026

• 综述 • 上一篇    下一篇

β-地中海贫血基因治疗的技术进展、临床证据与转化挑战

胡东杰, 陈莉萍, 梁斌, 李万旺, 吴超, 蔡少锋, 洪卧霞, 李尚霖, 陈群蓉   

  1. 深圳市宝安区人民医院输血科,广东深圳 518101
  • 收稿日期:2026-09-02 修回日期:2026-09-23 出版日期:2026-10-20 发布日期:2026-11-11
  • 通讯作者: 陈群蓉,主要从事临床输血方面的研究,(E-mail)chenqunronglh@aliyun.com。
  • 作者简介:胡东杰,主要从事地中海贫血和细胞治疗方面的研究,(E-mail)hudongjie1994@126.com。

Gene Therapy for β-Thalassemia: Technological Advances, Clinical Evidence, and Translational Challenges

HU Dongjie, CHEN Liping, LIANG Bin, LI Wanwang, WU Chao, CAI Shaofeng, HONG Woxia, LI Shanglin, CHEN Qunrong   

  1. Department of Blood Transfusion, Bao'an District People's Hospital of Shenzhen, Shenzhen, Guangdong 518101
  • Received:2026-09-02 Revised:2026-09-23 Online:2026-10-20 Published:2026-11-11

摘要: β-地中海贫血是由β-珠蛋白基因致病变异引起的常染色体隐性血红蛋白病。输血联合铁螯合可改善患者生存,但不能纠正遗传缺陷,自体造血干/祖细胞(HSPC)基因治疗为实现持久输血非依赖提供了新选择。本文梳理β-地中海贫血基因治疗的技术进展、临床证据及转化挑战。慢病毒基因补充策略将外源 β-珠蛋白表达盒整合入基因组,靶向BCL11A红系增强子的CRISPR核酸酶编辑通过重新激活胎儿血红蛋白发挥作用,相应代表性产品已获监管批准;核酸酶还可编辑HBG1/HBG2启动子,碱基编辑可在不引入程序化双链断裂的情况下重写胎儿血红蛋白调控元件,也可修复部分适配的β-珠蛋白基因致病变异,调控型碱基编辑已进入早期临床,但其直接修复范围受转换类型等条件限制;先导编辑理论上可实现全部12类碱基替换及部分小片段插入和缺失修复,但直接β-珠蛋白基因碱基修复和先导编辑仍处于临床前阶段。上述技术并非简单的“新旧更替”,其应用取决于编辑精确性、长期造血干细胞适能、预处理毒性、产品一致性、制造成本及患者可及性。

关键词: β-地中海贫血, 基因补充, 核酸酶编辑, 碱基编辑, 先导编辑, 胎儿血红蛋白, 造血干/祖细胞, 精准修复

Abstract: β-Thalassemia is an autosomal recessive hemoglobin disorder caused by pathogenic variants in the β-globin gene. Red blood cell transfusion with iron chelation improves patient survival but cannot correct the underlying genetic defect. Autologous hematopoietic stem and progenitor cell gene therapy offers a novel strategy to achieve sustained transfusion independence. This review summarizes the technical advances, clinical evidence, and translational challenges of gene therapy for β-thalassemia. Lentiviral gene addition delivers an exogenous β-globin expression cassette for genomic integration, whereas CRISPR nuclease editing targeting the BCL11A erythroid enhancer reactivates fetal hemoglobin. Representative products of these strategies have obtained regulatory approvals. Nuclease-mediated editing can also target the HBG1/HBG2 promoters. Base editing enables modification of fetal hemoglobin regulatory elements without generating programmed DNA double-strand breaks, and it can repair selected eligible pathogenic variants within the β-globin gene. Base editing for fetal hemoglobin regulation has entered early-stage clinical development, yet the scope of its direct gene repair is constrained by permissible base conversion types and other limitations. Prime editing can theoretically mediate all 12 classes of base substitutions and correct a subset of small insertions and deletions. Nevertheless, direct repair of the β-globin gene via base editing and prime editing is still confined to preclinical investigation. These technologies are not a simple "new-for-old replacement" of platforms. Their clinical utility is determined by editing accuracy, long-term HSPC fitness, conditioning regimen toxicity, product consistency, manufacturing costs and patient accessibility.

Key words: β-thalassemia, Gene addition, Nuclease editing, Base editing, Prime editing, Fetal hemoglobin, Hematopoietic stem and progenitor cells, Precision genome repair

中图分类号: